Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
T.MAN Pharmaceutical PCLBKK:TMAN -0.96%18 5-Year Yield-on-Cost % is 5.44 as of Sep. 13, 2026, which is 36% above its 10-year median of 4.00. GuruFocus rates BKK:TMAN with a GF Score™ of 18/100. Among 507 Drug Manufacturers companies, T.MAN Pharmaceutical PCL ranks better than 73.57% on this metric.
The historical rank and industry rank for T.MAN Pharmaceutical PCL's 5-Year Yield-on-Cost % or its related term are showing as below:
BKK:TMAN'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.6 Med: 4 Max: 5.44
Current: 5.44
During the past 4 years, T.MAN Pharmaceutical PCL's highest Yield on Cost was 5.44. The lowest was 1.60. And the median was 4.00.
BKK:TMAN's 5-Year Yield-on-Cost % is ranked better than 73.57% of 507
companies
in the Drug Manufacturers industry
Industry Median: 2.41
vs BKK:TMAN: 5.44
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
T.MAN Pharmaceutical PCL 5-Year Yield-on-Cost % Related Terms
BKK:TMAN vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, T.MAN Pharmaceutical PCL's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
T.MAN Pharmaceutical PCL 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, T.MAN Pharmaceutical PCL's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where T.MAN Pharmaceutical PCL's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
T.MAN Pharmaceutical PCL (BKK:TMAN) has a 5-Year Yield-on-Cost % of 5.44 as of Sep. 13, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on T.MAN Pharmaceutical PCL and its competitors. This is 36% above median its historical median of 4.00. Over the past decade, T.MAN Pharmaceutical PCL's 5-Year Yield-on-Cost % has ranged from 1.60 to 5.44. According to the industry distribution chart, T.MAN Pharmaceutical PCL ranks #134 out of 507 companies in the Drug Manufacturers industry, placing it in the top 26.4%.
Is T.MAN Pharmaceutical PCL's 5-Year Yield-on-Cost % too high?
T.MAN Pharmaceutical PCL's current 5-Year Yield-on-Cost % of 5.44 is 36% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.60 to a high of 5.44. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.41. T.MAN Pharmaceutical PCL's value of 5.44 is 125.7% above this industry median. Based on the distribution chart, T.MAN Pharmaceutical PCL ranks #134 out of 507 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, T.MAN Pharmaceutical PCL has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does T.MAN Pharmaceutical PCL's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, T.MAN Pharmaceutical PCL ranks #134 out of 507 companies for 5-Year Yield-on-Cost %. This puts T.MAN Pharmaceutical PCL in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.41. T.MAN Pharmaceutical PCL's value of 5.44 is 125.7% above this benchmark. Historically, T.MAN Pharmaceutical PCL's own 5-Year Yield-on-Cost % has ranged from 1.60 to 5.44 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 2.41, T.MAN Pharmaceutical PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.41, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. T.MAN Pharmaceutical PCL's current 5-Year Yield-on-Cost % of 5.44 is 125.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on T.MAN Pharmaceutical PCL and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. T.MAN Pharmaceutical PCL's current 5-Year Yield-on-Cost % is 5.44, which is 36% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is T.MAN Pharmaceutical PCL stock overvalued right now?
T.MAN Pharmaceutical PCL (BKK:TMAN) has a current 5-Year Yield-on-Cost % of 5.44. The current 5-Year Yield-on-Cost % is 5.44, which is 36% above median its 10-year median of 4.00 and 125.7% above the Drug Manufacturers industry median of 2.41. T.MAN Pharmaceutical PCL's overall GF Score™ is 18/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For T.MAN Pharmaceutical PCL (BKK:TMAN), the current 5-Year Yield-on-Cost % is 5.44 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
T.MAN Pharmaceutical PCL is engaged in purchasing, importing, manufacturing, and distributing original equipment and in manufacturing, distributing, and exporting modern medicines, traditional medicines, dietary supplements, and healthcare products for the healthcare industry. It offers products through brands such as T.Nutrition, T.Derma, Mommy&Me, TMT, Heaven Herb, and T.Pharmaceutical. The company's reportable segments are: Segment for manufactured products under own brand, which derives key revenue, Segment for manufactured products under third parties' brand, and Segment for trading products.
18GF Score
Get the complete analysis for BKK:TMAN
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:TMAN has been successfully added to your 
